Role of arginine vasopressin receptor antagonists in hyponatremia in the elderly

Geriatrics

Volumn 62, Issue 7, 2007, Pages 20-26

  Miller, Myron ^a,b  

^a SINAI HOSPITAL OF BALTIMORE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aquaretics; Arginine vasopressin (AVP); Hyponatremia; SIADH

Indexed keywords

ARGIPRESSIN; ARGIPRESSIN RECEPTOR; ARGIPRESSIN RECEPTOR BLOCKING AGENT; CONIVAPTAN; DEMECLOCYCLINE; FUROSEMIDE; LIXIVAPTAN; PLACEBO; RECEPTOR BLOCKING AGENT; SATAVAPTAN; SODIUM ION; TOLVAPTAN; UNCLASSIFIED DRUG; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V1B RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ALGORITHM; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG EFFICACY; FLUID BALANCE; HUMAN; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; INJECTION SITE REACTION; LIVER CIRRHOSIS; LOADING DRUG DOSE; NURSING HOME PATIENT; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; POLYURIA; PREVALENCE; REVIEW; SIDE EFFECT; SODIUM BALANCE; SODIUM BLOOD LEVEL; THIRST; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; WATER DEPRIVATION; XEROSTOMIA;

AGED; ARGININE VASOPRESSIN; HUMANS; HYPONATREMIA; RECEPTORS, VASOPRESSIN;

EID: 34547568387     PISSN: 0016867X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med. 2000;342(21):1581-1589.
2. Adrogué HJ. Consequences of inadequate management of hyponatremia. Am J Nephrol. 2005;25(3):240-249.
3. Janicic N, Verbalis JG. Evaluation and management of hypo-osmolality in hospitalized patients. Endocrinol Metab Clin North Am. 2003;32(2):459-481.
4. Kugler JP Hustead T. Hyponatremia and hypernatremia in the elderly. Am Fam Physician. 2000;61(12):3623-3630.
5. Miller M, Morley JE, Rubenstein LZ. Hyponatremia in a nursing home population. J Am Geriatr Soc. 1995;43(12):1410-1413.
6. Miller M, Hecker MS, Friedlander DA, Carter JM. Apparent idiopathic hyponatremia in an ambulatory geriatric population. J Am Geriatr Soc. 1996;44(4):404-408.
7. Anpalahan M. Chronic idiopathic hyponatremia in older people due to syndrome of inappropriate antidiuretic hormone secretion (SIADH) possibly related to aging. J Am Geriatr Soc. 2001;49(6):788-792.
8. Kleinfeld M, Casimir M, Borra S. Hyponatremia as observed in a chronic disease facility. J Am Geriatr Soc. 1979; 27(4):156-161.
9. Sunderam SG, Mankikar GD. Hyponatraemia in the elderly. Age Aging. 1983;12(1):77-80.
10. Lim JK, Yap KB. Hyponatraemia in hospitalised elderly patients. Med J Malaysia. 2001;56(2):232-235.
11. Terzian C, Frye EB, Piotrowski ZH. Admission hyponatremia in the elderly; factors influencing prognosis. J Gen Intern Med. 1994;9(2):89-91.
12. Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290(19):2581-2587.
13. Chin MH, Goldman L. Correlates of major complications or death in patients admitted to the hospital with congestive heart failure. Arch Intern Med. 1996;156(16):1814-1820.
14. Beck LH. The aging kidney: defending a delicate balance of fluid and electrolytes. Geriatrics. 2000;55(4):26-32.
15. Beck LH. Changes in renal function with aging. Clin Geriatr Med. 1998;14(2):199-209.
16. Davies DF, Shock NW. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest. 1950;29(5):496-507.
17. Crowe MJ, Forsling ML, Rolls BJ, et al. Altered water excretion in healthy elderly men. Age Ageing. 1987;16(5):285-293.
18. Epstein M, Hollenberg NK. Age as a determinant of renal sodium conservation in normal man. J Lab Clin Med. 1976;87(3):411-417.
19. Macías-Núñez JF, Garcia Iglesias C, Bondía Román A, et al. Renal handling of sodium in old people: a functional study. Age Ageing. 1978;7(3):178-181.
20. Helderman JH, Vestal RE, Rowe JW, et al. The response of arginine vasopressin to intravenous ethanol and hypertonic saline in man: the impact of aging. J Gerontol. 1978;33(1):39-47.
21. Baylis PH. The syndrome of inappropriate antidiuretic hormone secretion. Int J Biochem Cell Biol. 2003;35(11):1495-1499.
22. Miller M. Hyponatremia: age-related risk factors and therapy decisions. Geriatrics. 1998;53(7):32-42.
23. Kirby D, Ames D. Hyponatraemia and selective serotonin re-uptake inhibitors in elderly patients. Int J Geriatr Psychiatry. 2001;16(5):484-493.
24. Liu BA, Mittmann N, Knowles SR, et al. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. CMAJ. 1996;155(5):519-527.
25. Fried LF, Palevsky PM. Hyponatremia and hypernatremia. Med Clin North Am. 1997;81(3):585-609.
26. Miller M. Syndromes of excess antidiuretic hormone release. Crit Care Clin. 2001;17(1):11-23.
27. Luckey AE, Parsa CJ. Fluid and electrolytes in the aged. Arch Surg. 2003;138(10):1055-1060.
28. Renneboog B, Musch W, Vandemergel X, et al. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med. 2006;119(1):71.e1-8.
29. Gross P, Reimann D, Henschkowski J, et al. Treatment of severe hyponatremia: conventional and novel aspects. J Am Soc Nephrol. 2001;12(suppl 17):S10-S14.
30. Miller M. Hormonal aspects of fluid and sodium balance in the elderly. Endocrinol Metab Clin North Am. 1995;24(2):233-253.
31. Anderson RJ. Hospital-associated hyponatremia. Kidney Int. 1986;29(6):1237-1247.
32. Verbalis JG. Vasopressin V2 receptor antagonists. J Mol Endocrinol. 2002;29(1):1-9.
33. Wong LL, Verbalis JG. Vasopressin V2 receptor antagonists. Cardiovasc Res. 2001;51(3):391-402.
34. Kinter LB, Huffman WF, Stassen FL. Antagonists of the antidiuretic activity of vasopressin. Am J Physiol. 1988;254(2 pt 2):F165-F177.
35. Rose CE Jr, Rose KY, Kinter LB. Effect of V1/V2-receptor antagonism on renal function and response to vasopressin in conscious dogs. Am J Physiol. 1991;260(2 pt 2):F273-F282.
36. Gross P. Correction of hyponatremia. Semin Nephrol. 2001;21(3):269-272.
37. Thibonnier M, Coles P, Thibonnier A, et al. The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists. Annu Rev Pharmacol Toxicol. 2001;41:175-202.
38. Verbalis JG. AVP receptor antagonists as aquaretics: review and assessment of clinical data. Cleve Clin J Med. 2006;73(suppl 3):S24-S33.
39. Goldsmith SR. Is there a cardiovascular rationale for the use of combined vasopressin V1A/V2 receptor antagonists? Am J Med. 2006;119(7A):S93-S96.
40. Gheorghiade M, Gattis WA, Barbagelata A, et al, for the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure Investigators. Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. Am Heart J. 2003;145(2 suppl):S51-S54.
41. Gheorghiade M, Niazi I, Ouyang J, et al, for the Tolvaptan Investigators. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation. 2003;107(21):2690-2696.
42. Gheorghiade M, Gattis WA, O'Connor CM, et al, for the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291(16):1963-1971.
43. 2-receptor antagonist for hyponatremia. N Engl J Med. 2006;355(20):2099-2112.
44. Gerbes AL, Gulberg V, Gines P, et al, for the VPA Study Group. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology. 2003;124(4):933-939.
45. Wong F, Blei AT, Blendis LM, et al, for The North American VPA-985 Study Group. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology. 2003;37(1):182-191.
46. 2 antagonist conivaptan increases serum sodium concentration and effective water clearance in hyponatremia. Abstract SA-P0254. J Am Soc Nephrol. 2004;15:356A.
47. Verbalis JG, Ghali JK, Gross P, et al. Conivaptan, a novel arginine vasopressin antagonist, produced aquaresis and increased serum sodium concentration in patients with euvolemic and hypervolemic hyponatremia. Abstract 98. Pharmacotherapy. 2005;25(10):1454.
48. Verbalis JG, Ghali JK, Gross P, et al. Efficacy and safety of the vasopressin antagonist conivaptan in patients with euvolemic hyponatremia evaluated in a phase III clinical trial. Abstract 8550. J Clin Oncol. 2006;24(suppl 18S):480S.
49. 2 antagonist, increased serum sodium and effective water clearance in patients with euvolemic or hypervolemic hyponatremia. Abstract SA-P0243. J Am Soc Nephrol. 2004;15:355A.
50. 2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab. 2006;91(6):2145- 2152.
51. Soupart A, Gross P, Legros JJ, et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with SR 121463B, an orally active, nonpeptide, vasopressin V-2 receptor antagonist. Abstract SU-PO140. J Am Soc Nephrol. 2004;15:563A.